159.08
전일 마감가:
$157.31
열려 있는:
$158
하루 거래량:
234.06K
Relative Volume:
1.19
시가총액:
$3.12B
수익:
$152.42M
순이익/손실:
$45.24M
주가수익비율:
63.38
EPS:
2.51
순현금흐름:
$6.97M
1주 성능:
+5.30%
1개월 성능:
+20.10%
6개월 성능:
+31.83%
1년 성능:
+53.52%
리간드 파마 Stock (LGND) Company Profile
명칭
Ligand Pharmaceuticals Inc
전화
858-550-7500
주소
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
LGND을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
LGND
Ligand Pharmaceuticals Inc
|
159.08 | 3.02B | 152.42M | 45.24M | 6.97M | 2.51 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
리간드 파마 Stock (LGND) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-10 | 개시 | Stifel | Buy |
2024-10-03 | 개시 | Oppenheimer | Outperform |
2024-07-30 | 개시 | RBC Capital Mkts | Outperform |
2021-04-14 | 재개 | Stephens | Overweight |
2021-02-04 | 재확인 | H.C. Wainwright | Buy |
2020-10-06 | 개시 | Barclays | Overweight |
2020-03-24 | 다운그레이드 | Argus | Buy → Hold |
2020-03-10 | 개시 | Guggenheim | Neutral |
2020-02-06 | 개시 | The Benchmark Company | Buy |
2019-09-19 | 업그레이드 | Barclays | Equal Weight → Overweight |
2019-06-11 | 개시 | Barclays | Equal Weight |
2019-05-03 | 재확인 | H.C. Wainwright | Buy |
2019-03-06 | 재확인 | H.C. Wainwright | Buy |
2018-10-29 | 업그레이드 | ROTH Capital | Neutral → Buy |
2018-10-02 | 재확인 | H.C. Wainwright | Buy |
2018-09-11 | 재확인 | Argus | Buy |
2018-08-17 | 개시 | Goldman | Neutral |
2018-08-08 | 다운그레이드 | ROTH Capital | Buy → Neutral |
2018-06-21 | 개시 | Argus | Buy |
2017-12-27 | 재확인 | H.C. Wainwright | Buy |
2017-09-05 | 재개 | H.C. Wainwright | Buy |
2016-10-05 | 재확인 | H.C. Wainwright | Buy |
2016-08-05 | 다운그레이드 | Deutsche Bank | Hold → Sell |
2016-03-11 | 개시 | Sidoti | Buy |
2016-03-03 | 개시 | H.C. Wainwright | Buy |
모두보기
리간드 파마 주식(LGND)의 최신 뉴스
Ligand Q1 2025 slides: Revenue surges 46%, strategic Pelthos merger announced - Investing.com
Ligand to Participate in September Investor Conferences | LGND Stock News - GuruFocus
Ligand Pharmaceuticals to Participate in Upcoming Investor Conferences in September 2025 - Quiver Quantitative
Ligand to Participate in September Investor Conferences - Yahoo Finance
Published on: 2025-08-18 01:20:46 - sundaytimes.kr
Ligand Pharmaceuticals to offer $400M convertible senior notes in private placement - MSN
Why Ligand Pharmaceuticals Incorporated stock attracts strong analyst attentionJuly 2025 News Drivers & Daily Growth Stock Tips - beatles.ru
What to do if you’re stuck in Ligand Pharmaceuticals IncorporatedDividend Hike & AI Forecast for Swing Trade Picks - Newser
Ligand Pharmaceuticals Incorporated Shows Early Signs of Technical Strength2025 Trading Recap & Free High Accuracy Swing Entry Alerts - sundaytimes.kr
Ligand Pharmaceuticals raises $400mln through convertible senior notes offering. - AInvest
Ligand Pharma Completes $460M Convertible Notes Offering - TipRanks
Ligand Pharmaceuticals completes $460 million convertible notes offering By Investing.com - Investing.com Canada
Ligand Announces Closing of Convertible Senior Notes Offering - Yahoo Finance
Detecting support and resistance levels for Ligand Pharmaceuticals IncorporatedWeekly Market Summary & Expert Approved Momentum Ideas - Newser
US Bancorp DE Purchases 3,301 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $185.00 - MarketBeat
Ligand Pharmaceuticals shares rise 3.65% intraday after pricing $400 million convertible senior notes offering. - AInvest
Ligand's $400M Convertible Notes Offering: A Strategic Move for M&A-Driven Growth and Shareholder Value - AInvest
Ligand Pharmaceuticals Stock (LGND) Opinions on $400M Convertible Notes Offering - Quiver Quantitative
Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates - Yahoo Finance
Ligand Prices $400 Million Convertible Senior Notes Offering - MarketScreener
Ligand Pharmaceuticals Experiences Strong Q2 Earnings with Robust Revenue Growth, Successful Mergers and Investments, and Raised Financial Guidance. - AInvest
Ligand Pharmaceuticals Prices Offering Of $400 Mln Of Senior Notes - Nasdaq
Analysts Bullish on Insmed and Ligand Pharma: Strong Buy Ratings and High Price Targets - AInvest
Ligand Pharmaceuticals Secures $400M in Convertible Debt Offering - AInvest
Ligand Pharmaceuticals' Convertible Notes Offering: A Strategic Move for Capital Optimization and Growth - AInvest
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering | LGND Stock News - GuruFocus
Ligand Pharmaceuticals prices $400 million convertible notes offering By Investing.com - Investing.com Canada
Ligand's Convertible Notes Offering: Balancing Dilution Risks and Strategic Flexibility in Biopharma Financing - AInvest
Ligand Pharmaceuticals Prices $400 Million Convertible Senior Notes Due 2030 - Quiver Quantitative
Ligand Secures $400M Convertible Note Deal: Key Terms Reveal 0.75% Rate and $15M Share Buyback - Stock Titan
Ligand prices $400 million convertible senior notes offering - MarketScreener
Ligand Pharmaceuticals Prices $400M Convertible Senior Notes Offering - AInvest
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - MarketScreener
Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering - GlobeNewswire Inc.
LGNDLigand Pharma Latest Stock News & Market Updates - Stock Titan
Ligand Pharmaceuticals Inc. Reports Strong Q2 Earnings - TipRanks
LGND: Getting In Tune with MedTech - Zacks Small Cap Research
Ligand Pharmaceuticals Plans $400 Million Convertible Senior Notes Offering - MarketScreener
Ligand Pharma Proposes Private Offering Of $400 Mln Of Sr. Notes - Nasdaq
Ligand Pharmaceuticals shares fall 4.06% premarket after announcing a $400 million convertible senior notes offering. - AInvest
Ligand Announces $400M Convertible Senior Notes Offering Due 2030. - AInvest
Ligand Pharmaceuticals plans $400 million convertible notes offering By Investing.com - Investing.com Canada
Ligand Pharmaceuticals to Offer $400mln Convertible Senior Notes Due 2030. - AInvest
Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 - MarketScreener
Ligand Launches Major $400M Convertible Notes Deal with Strategic Share Buyback Plan - Stock Titan
Analyzing Ligand Pharmaceuticals Incorporated with risk reward ratio chartsMonthly Long-Term Market Recap and Summary - Newser
Ligand's Q2 2025: Unraveling Contradictions in Pelthos Launch, Deal Strategies, and Market Dynamics - AInvest
Will Ligand Pharmaceuticals Incorporated Recover After Recent DeclineStable Entry High Return Opportunities in Focus - beatles.ru
Royal Bank Of Canada Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) Stock - Defense World
A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $157 to $185 - 富途牛牛
리간드 파마 (LGND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):